Compare Harmony Gold Mining Co. (HMY) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Harmony Gold Mining Co. vs TG Therapeutics Inc — how do they compare? Harmony Gold Mining Co. trades at $16.88 (market cap $10.02B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: Harmony Gold Mining Co. is the larger of the two by market cap, and Harmony Gold Mining Co. pays a 4.63% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Harmony Gold Mining Co. for 45 Days and TG Therapeutics Inc for 16 Days on average.
| HMY | TGTX | |
|---|---|---|
Market Cap | $10.02B | $8.16B |
Volume | 3,643,683 | 1,735,121 |
Sector | Basic Materials | Health |
52-Week High | $26.04 | $59.06 |
52-Week Low | $13.32 | $26.94 |
Typical Hold Time | 45 Days | 16 Days |
Enterprise Value | $10.07B | $8.37B |
Dividend Yield | 4.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Harmony Gold Mining (HMY) trades at $16.88, up 2.37% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. Fundamentally, the company shows strong profitability with a 29.57% net income margin and robust revenue growth, climbing from $42.6B in 2022 to $73.9B in 2025. Recent earnings have been mixed, with two beats and two misses in the last four quarters. Analyst sentiment is cautious, with a consensus leaning heavily toward Hold.
The outlook for HMY is balanced; its low P/E of 6.02 and expansion into copper production offer value, but bearish technicals and high hold ratings suggest near-term volatility. Key risks include execution of growth projects and commodity price fluctuations, while institutional interest remains a supportive factor.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Harmony Gold Mining Co.
Harmony Gold Mining Co Ltd is a gold mining and exploration company having operations in South Africa and Papua New Guinea (PNG). Its projects include Bambanani, Joel, Masimong, Phakisa, Target 1, Tshepong, Unisel, Doornkop, and Kusasalethu. The group's segments are Tshepong Operations, Bambanani, Joel, Doornkop, Moab Khotsong, Hidden Valley, Target 1, Kusasalethu, Masimong, Unisel, and all other surface operations.
Read more on HMY →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
